Cancer immunotherapy targeting the CD47/SIRPα axis

European Journal of Cancer

Volumn 76, Issue , 2017, Pages 100-109

  Weiskopf, Kipp ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer immunotherapy; CD47; Immune checkpoint; Immuno oncology; Macrophage; Phagocytosis; SIRPa

Indexed keywords

ANTINEOPLASTIC AGENT; CD47 ANTIGEN; CD47 SIGNAL REGULATORY PROTEIN ALPHA BLOCKING AGENT; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; REGULATOR PROTEIN; SIGNAL REGULATORY PROTEIN ALPHA; UNCLASSIFIED DRUG; CANCER ANTIBODY; DIFFERENTIATION ANTIGEN; IMMUNOGLOBULIN RECEPTOR; PTPNS1 PROTEIN, MOUSE; SIRPA PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; DRUG TARGETING; HUMAN; IMMUNOPATHOGENESIS; MALIGNANT NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIGEN PRESENTATION; BONE MARROW CELL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; MACROPHAGE; MOLECULARLY TARGETED THERAPY; MOUSE; NEOPLASMS; PHAGOCYTOSIS; PROCEDURES;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGEN PRESENTATION; ANTIGENS, CD47; ANTIGENS, DIFFERENTIATION; HUMANS; IMMUNOTHERAPY; MACROPHAGES; MICE; MOLECULAR TARGETED THERAPY; MYELOID CELLS; NEOPLASMS; PHAGOCYTOSIS; RECEPTORS, IMMUNOLOGIC;

EID: 85014737988     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.02.013     Document Type: Review

References (76)

1. [1] Poels, L.G., Peters, D., van Megen, Y., Vooijs, G.P., Verheyen, R.N., Willemen, A., et al. Monoclonal antibody against human ovarian tumor-associated antigens. J Natl Cancer Inst 76 (1986), 781–791.
2. [2] Brown, E., Hooper, L., Ho, T., Gresham, H., Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins. J Cell Biol 111 (1990), 2785–2794.
3. [3] Mawby, W.J., Holmes, C.H., Anstee, D.J., Spring, F.A., Tanner, M.J., Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. Biochem J 304:Pt 2 (1994), 525–530.
4. [4] Oldenborg, P.A., Zheleznyak, A., Fang, Y.F., Lagenaur, C.F., Gresham, H.D., Lindberg, F.P., Role of CD47 as a marker of self on red blood cells. Science 288 (2000), 2051–2054.
5. [5] Olsson, M., Bruhns, P., Frazier, W.A., Ravetch, J.V., Oldenborg, P.A., Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood 105 (2005), 3577–3582.
6. [6] Blazar, B.R., Lindberg, F.P., Ingulli, E., Panoskaltsis-Mortari, A., Oldenborg, P.A., Iizuka, K., et al. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. J Exp Med 194 (2001), 541–549.
7. [7] Wang, H., VerHalen, J., Madariaga, M.L., Xiang, S., Wang, S., Lan, P., et al. Attenuation of phagocytosis of xenogeneic cells by manipulating CD47. Blood 109 (2007), 836–842.
8. [8] Takenaka, K., Prasolava, T.K., Wang, J.C., Mortin-Toth, S.M., Khalouei, S., Gan, O.I., et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol 8 (2007), 1313–1323.
9. [9] Yamauchi, T., Takenaka, K., Urata, S., Shima, T., Kikushige, Y., Tokuyama, T., et al. Polymorphic Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment. Blood 121 (2013), 1316–1325.
10. [10] Hatherley, D., Harlos, K., Dunlop, D.C., Stuart, D.I., Barclay, A.N., The structure of the macrophage signal regulatory protein alpha (SIRPalpha) inhibitory receptor reveals a binding face reminiscent of that used by T cell receptors. J Biol Chem 282 (2007), 14567–14575.
11. [11] Hatherley, D., Graham, S.C., Turner, J., Harlos, K., Stuart, D.I., Barclay, A.N., Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. Mol Cell 31 (2008), 266–277.
12. [12] Liu, Y., Tong, Q., Zhou, Y., Lee, H.W., Yang, J.J., Buhring, H.J., et al. Functional elements on SIRPalpha IgV domain mediate cell surface binding to CD47. J Mol Biol 365 (2007), 680–693.
13. [13] Kharitonenkov, A., Chen, Z., Sures, I., Wang, H., Schilling, J., Ullrich, A., A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 386 (1997), 181–186.
14. [14] Barclay, A.N., Brown, M.H., The SIRP family of receptors and immune regulation. Nat Rev Immunol 6 (2006), 457–464.
15. [15] Adams, S., van der Laan, L.J., Vernon-Wilson, E., Renardel de Lavalette, C., Dopp, E.A., Dijkstra, C.D., et al. Signal-regulatory protein is selectively expressed by myeloid and neuronal cells. J Immunol 161 (1998), 1853–1859.
16. [16] Jiang, P., Lagenaur, C.F., Narayanan, V., Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J Biol Chem 274 (1999), 559–562.
17. [17] Seiffert, M., Cant, C., Chen, Z., Rappold, I., Brugger, W., Kanz, L., et al. Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. Blood 94 (1999), 3633–3643.
18. [18] Ho, C.C., Guo, N., Sockolosky, J.T., Ring, A.M., Weiskopf, K., Ozkan, E., et al. “Velcro” engineering of high affinity CD47 ectodomain as signal regulatory protein alpha (SIRPalpha) antagonists that enhance antibody-dependent cellular phagocytosis. J Biol Chem 290 (2015), 12650–12663.
19. [19] Weiskopf, K., Schnorr, P.J., Pang, W.W., Chao, M.P., Chhabra, A., Seita, J., et al. Myeloid cell origins, differentiation, and clinical implications. Microbiol Spectr, 4, 2016.
20. [20] Barclay, A.N., Van den Berg, T.K., The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target. Annu Rev Immunol 32 (2014), 25–50.
21. [21] Lienard, H., Bruhns, P., Malbec, O., Fridman, W.H., Daeron, M., Signal regulatory proteins negatively regulate immunoreceptor-dependent cell activation. J Biol Chem 274 (1999), 32493–32499.
22. [22] Tsai, R.K., Discher, D.E., Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol 180 (2008), 989–1003.
23. [23] Jaiswal, S., Jamieson, C.H., Pang, W.W., Park, C.Y., Chao, M.P., Majeti, R., et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138 (2009), 271–285.
24. [24] Majeti, R., Chao, M.P., Alizadeh, A.A., Pang, W.W., Jaiswal, S., Gibbs, K.D. Jr., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138 (2009), 286–299.
25. [25] Chao, M.P., Alizadeh, A.A., Tang, C., Myklebust, J.H., Varghese, B., Gill, S., et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142 (2010), 699–713.
26. [26] Chao, M.P., Alizadeh, A.A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71 (2011), 1374–1384.
27. [27] Kim, D., Wang, J., Willingham, S.B., Martin, R., Wernig, G., Weissman, I.L., Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 26 (2012), 2538–2545.
28. [28] Willingham, S.B., Volkmer, J.P., Gentles, A.J., Sahoo, D., Dalerba, P., Mitra, S.S., et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 109 (2012), 6662–6667.
29. [29] Edris, B., Weiskopf, K., Volkmer, A.K., Volkmer, J.P., Willingham, S.B., Contreras-Trujillo, H., et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A 109 (2012), 6656–6661.
30. [30] Krampitz, G.W., George, B.M., Willingham, S.B., Volkmer, J.P., Weiskopf, K., Jahchan, N., et al. Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proc Natl Acad Sci U S A 113 (2016), 4464–4469.
31. [31] Weiskopf, K., Jahchan, N.S., Schnorr, P.J., Cristea, S., Ring, A.M., Maute, R.L., et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest 126 (2016), 2610–2620.
32. [32] Ngo, M., Han, A., Lakatos, A., Sahoo, D., Hachey, S.J., Weiskopf, K., et al. Antibody therapy targeting CD47 and CD271 effectively suppresses melanoma metastasis in patient-derived xenografts. Cell Rep 16:6 (2016 Aug 9), 1701–1716 http://dx.doi.org/10.1016/j.celrep.2016.07.004. Epub 2016 Jul 28.
33. [33] Weiskopf, K., Ring, A.M., Ho, C.C., Volkmer, J.P., Levin, A.M., Volkmer, A.K., et al. Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341 (2013), 88–91.
34. [34] Tseng, D., Volkmer, J.P., Willingham, S.B., Contreras-Trujillo, H., Fathman, J.W., Fernhoff, N.B., et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A 110 (2013), 11103–11108.
35. [35] Murray, P.J., Wynn, T.A., Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11 (2011), 723–737.
36. [36] Martinez, F.O., Gordon, S., The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep, 6, 2014, 13.
37. [37] Zhang, M., Hutter, G., Kahn, S.A., Azad, T.D., Gholamin, S., Xu, C.Y., et al. Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo. PLoS One, 11, 2016, e0153550.
38. [38] Zhao, X.W., van Beek, E.M., Schornagel, K., Van der Maaden, H., Van Houdt, M., Otten, M.A., et al. CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A 108 (2011), 18342–18347.
39. [39] Yi, T., Li, J., Chen, H., Wu, J., An, J., Xu, Y., et al. Splenic dendritic cells survey red blood cells for missing self-CD47 to trigger adaptive immune responses. Immunity 43 (2015), 764–775.
40. [40] Liu, X., Pu, Y., Cron, K., Deng, L., Kline, J., Frazier, W.A., et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 21 (2015), 1209–1215.
41. [41] Soto-Pantoja, D.R., Terabe, M., Ghosh, A., Ridnour, L.A., DeGraff, W.G., Wink, D.A., et al. CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res 74 (2014), 6771–6783.
42. [42] Kim, M.J., Lee, J.C., Lee, J.J., Kim, S., Lee, S.G., Park, S.W., et al. Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. Tumour Biol 29 (2008), 28–34.
43. [43] Brown, E.J., Frazier, W.A., Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 11 (2001), 130–135.
44. [44] Isenberg, J.S., Ridnour, L.A., Dimitry, J., Frazier, W.A., Wink, D.A., Roberts, D.D., CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 281 (2006), 26069–26080.
45. [45] Mateo, V., Lagneaux, L., Bron, D., Biron, G., Armant, M., Delespesse, G., et al. CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia. Nat Med 5 (1999), 1277–1284.
46. [46] Mateo, V., Brown, E.J., Biron, G., Rubio, M., Fischer, A., Deist, F.L., et al. Mechanisms of CD47-induced caspase-independent cell death in normal and leukemic cells: link between phosphatidylserine exposure and cytoskeleton organization. Blood 100 (2002), 2882–2890.
47. [47] Manna, P.P., Frazier, W.A., CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A. Cancer Res 64 (2004), 1026–1036.
48. [48] Kikuchi, Y., Uno, S., Kinoshita, Y., Yoshimura, Y., Iida, S., Wakahara, Y., et al. Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma. Leuk Res 29 (2005), 445–450.
49. [49] Weiskopf, K., Anderson, K.L., Ito, D., Schnorr, P.J., Tomiyasu, H., Ring, A.M., et al. Eradication of canine diffuse large B-cell lymphoma in a murine xenograft model with CD47 blockade and anti-CD20. Cancer Immunol Res 4 (2016), 1072–1087.
50. [50] Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One, 10, 2015, e0137345.
51. [51] Theocharides, A.P., Jin, L., Cheng, P.Y., Prasolava, T.K., Malko, A.V., Ho, J.M., et al. Disruption of SIRPalpha signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J Exp Med 209 (2012), 1883–1899.
52. [52] Wu, Y., Tibrewal, N., Birge, R.B., Phosphatidylserine recognition by phagocytes: a view to a kill. Trends Cell Biol 16 (2006), 189–197.
53. [53] Chao, M.P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A.A., Gentles, A.J., Volkmer, J., et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med, 2, 2010, 63ra94.
54. [54] Weiskopf, K., Weissman, I.L., Macrophages are critical effectors of antibody therapies for cancer. mAbs 7 (2015), 303–310.
55. [55] van Lookeren Campagne, M., Wiesmann, C., Brown, E.J., Macrophage complement receptors and pathogen clearance. Cell Microbiol 9 (2007), 2095–2102.
56. [56] Kawai, T., Akira, S., The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11 (2010), 373–384.
57. [57] Oldenborg, P.A., Gresham, H.D., Lindberg, F.P., CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med 193 (2001), 855–862.
58. [58] Weiskopf, K., Ring, A.M., Schnorr, P.J., Volkmer, J.P., Volkmer, A.K., Weissman, I.L., et al. Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPalpha variants. Oncoimmunology, 2, 2013, e25773.
59. [59] Yanagita, T., Murata, Y., Tanaka, D., Motegi, S.I., Arai, E., Daniwijaya, E.W., et al. Anti-SIRPalpha antibodies as a potential new tool for cancer immunotherapy. JCI Insight, 2, 2017, e89140.
60. [60] Fischer, N., Elson, G., Magistrelli, G., Dheilly, E., Fouque, N., Laurendon, A., et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun, 6, 2015, 6113.
61. [61] Piccione, E.C., Juarez, S., Liu, J., Tseng, S., Ryan, C.E., Narayanan, C., et al. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. mAbs 7 (2015), 946–956.
62. [62] Piccione, E.C., Juarez, S., Tseng, S., Liu, J., Stafford, M., Narayanan, C., et al. SIRPalpha-antibody fusion proteins selectively bind and eliminate dual antigen-expressing tumor cells. Clin Cancer Res 22:20 (2016 Oct 15), 5109–5119 Epub 2016 Apr 28.
63. [63] Ponce, L.P., Fenn, N.C., Moritz, N., Krupka, C., Kozik, J.H., Lauber, K., et al. SIRPalpha-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells. Oncotarget, 2017 Jan 4 http://dx.doi.org/10.18632/oncotarget.14500. [Epub ahead of print].
64. [64] Anniss, A.M., Sparrow, R.L., Expression of CD47 (integrin-associated protein) decreases on red blood cells during storage. Transfus Apher Sci 27 (2002), 233–238.
65. [65] Khandelwal, S., van Rooijen, N., Saxena, R.K., Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. Transfusion 47 (2007), 1725–1732.
66. [66] Pluen, A., Boucher, Y., Ramanujan, S., McKee, T.D., Gohongi, T., di Tomaso, E., et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A 98 (2001), 4628–4633.
67. [67] Wang, W., Wang, E.Q., Balthasar, J.P., Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84 (2008), 548–558.
68. [68] Sockolosky, J.T., Dougan, M., Ingram, J.R., Ho, C.C., Kauke, M.J., Almo, S.C., et al. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci U S A 113:19 (2016 May 10), E2646–E2654 http://dx.doi.org/10.1073/pnas.1604268113. Epub 2016 Apr 18.
69. [69] Kwong, P.D., Mascola, J.R., Nabel, G.J., Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol 13 (2013), 693–701.
70. [70] Caskey, M., Klein, F., Nussenzweig, M.C., Broadly neutralizing antibodies for HIV-1 prevention or immunotherapy. N Engl J Med 375 (2016), 2019–2021.
71. [71] Edwards, J.C., Szczepanski, L., Szechinski, J., Filipowicz-Sosnowska, A., Emery, P., Close, D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004), 2572–2581.
72. [72] Chhabra, A., Ring, A.M., Weiskopf, K., Schnorr, P.J., Gordon, S., Le, A.C., et al. Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Sci Transl Med, 8, 2016 351ra105.
73. [73] Czechowicz, A., Kraft, D., Weissman, I.L., Bhattacharya, D., Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 318 (2007), 1296–1299.
74. [74] Withrow, S.J., Vail, D.M., Page, R.L., Withrow & MacEwen's small animal clinical oncology. 5th ed., 2012, Saunders (Elsevier), St. Louis, MO.
75. [75] Ito, D., Frantz, A.M., Modiano, J.F., Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. Vet Immunol Immunopathol 159 (2014), 192–201.
76. [76] Rue, S.M., Eckelman, B.P., Efe, J.A., Bloink, K., Deveraux, Q.L., Lowery, D., et al. Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma. Vet Immunol Immunopathol 164 (2015), 148–159.